Edition:
United States

People: Oncternal Therapeutics Inc (ONCT.PH)

ONCT.PH on Philadelphia Stock Exchange

5.86USD
23 Aug 2019
Change (% chg)

$1.13 (+23.89%)
Prev Close
$4.73
Open
$5.86
Day's High
$5.86
Day's Low
$5.86
Volume
100
Avg. Vol
813
52-wk High
$25.50
52-wk Low
$0.77

Vincent, Richard 

Mr. Richard G. Vincent is Chief Financial Officer of the Company. He has served as Oncternal’s Chief Financial Officer since April 2017. From 2012 to the present, Mr. Vincent has worked as an independent Chief Financial Officer, and was Chief Financial Officer and Secretary of Sorrento Therapeutics from January 2011 through February 2015. From 2008 to January 2011, Mr. Vincent served as an independent Chief Financial Officer to several pharmaceutical, biotech and medical device companies, including Avalyn Pharma (co-founder), Meritage Pharma, and Elevation Pharmaceuticals. Mr. Vincent served as Chief Financial Officer for Verus Pharmaceuticals from 2004 to 2008, and Women First Healthcare from 2003 to 2005. Mr. Vincent’s areas of responsibility have spanned all areas of finance, treasury, investor and public relations, human resources, information technology, facilities and project management. From 1987 to 1995, Mr. Vincent held a number of positions with Deloitte & Touche LLP, the last of which was senior manager, where he specialized in emerging growth and publicly-reporting companies. Mr. Vincent became a Certified Public Accountant in California in 1989 and holds a B.S. degree in business with an emphasis in accounting from San Diego State University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --